Complement Inhibitor for Pre-eclampsia Prevention

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Current treatments for pre-eclampsia are ineffective, and there is a need for a satisfactory prevention or treatment method beyond delivery, as pre-eclampsia poses significant risks to maternal and fetal health worldwide, particularly in developing countries.

Innovation Solution

Administration of a complement inhibitor, such as a C1 esterase inhibitor, to prevent or treat pre-eclampsia by inhibiting the complement system, which can be in the form of a small molecule, protein, peptide, antibody, or enzyme, and can be administered via various routes including intravenous and subcutaneous methods.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If delivery of the baby is performed, then pre-eclampsia is resolved, but maternal and fetal morbidity and mortality occur before delivery

Engineering Contradiction:

Improveeffectiveness of treatmentVSAvoidmaternal and fetal morbidity and mortality

Core Design Contradiction:

ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The complement inhibitor is administered before the onset of pre-eclampsia symptoms or at early stages to prevent the development of hypertension and proteinuria, thereby avoiding maternal and fetal complications that would otherwise occur before delivery becomes necessary

Inventive Principle:

Principle #10Preliminary action

Solution Approach 2:

The complement inhibitor acts as an intermediary substance that blocks the harmful effects of placental-derived factors on maternal endothelium, preventing the cascade of endothelial dysfunction, vasoconstriction, and organ ischemia that leads to pre-eclampsia

Inventive Principle:

Principle #24Intermediary (Mediator)

2Object-affected harmful factors

If no treatment is administered, then pre-eclampsia progresses to severe complications, but existing treatments are not satisfactorily effective

Engineering Contradiction:

Improveseverity of pre-eclampsia complicationsVSAvoideffectiveness of available treatments

Core Design Contradiction:

Object-affected harmful factorsVSReliability

Solution Approach 1:

The invention converts the harmful overactive complement system into a beneficial target for inhibition, where blocking complement activation prevents endothelial damage and transforms the pathological process into a treatable condition with reduced severity

Inventive Principle:

Principle #22Blessing in disguise (Convert harm into benefit)

Solution Approach 2:

The complement inhibitor changes the physiological parameter of complement system activity from an overactive state that causes endothelial dysfunction to a inhibited state that prevents pre-eclampsia complications, thereby improving treatment effectiveness

Inventive Principle:

Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The use of complement inhibitors effectively delays the onset or reduces the severity of pre-eclampsia, as demonstrated by lower blood pressure and proteinuria in clinical studies, providing a promising alternative to existing treatments.

Implementation Method 1

administration of a complement inhibitor could be effective in the treatment of pre-eclampsia

Methodology Applied

Scientific EffectComplement system inhibition:

Data Source

PatentUS20240285736A1Treatment and prevention of pre-eclampsia

Publication Date: 2024.08.29 PHARMING INTPROP BV

AI summary

The present invention relates to the field of medicine, specifically to the prevention and treatment of pre-eclampsia.